NMN vs NR: Comparing the NAD+ Precursors

NAD+ is a coenzyme involved in energy metabolism and DNA repair, and its levels appear to decline with age. That observation has launched a small industry of supplements designed to raise it. The two most prominent are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). The common question — which is better? — turns out to be harder to answer than the marketing implies.

What each one is

NR and NMN are both precursors the body can convert toward NAD+. NR is one step further upstream; in most current models, NR is thought to be converted into NMN before continuing along the pathway. That detail fuels a long-running debate about whether NMN even enters cells directly or is broken down to NR first.

Both have human safety data, and several trials show that supplementing either one raises measurable NAD+ in blood. That part is reasonably well established.

The honest limit: raising a blood NAD+ marker is not the same as slowing aging, improving healthspan, or extending life. The downstream clinical benefits remain largely unproven in humans.

Where the evidence stands

• NR has the longer, cleaner human track record on the biomarker. A randomized, placebo-controlled trial of 133 healthy overweight adults (Conze et al., Scientific Reports, 2019) found NR raised whole-blood NAD+ by up to 142% at 1,000 mg/day, dose-dependently and without excess adverse events.
• NMN has accumulated human trials more recently. A systematic review of 10 randomized controlled trials (437 participants, doses 150–1,200 mg/day; Cureus, August 2024) found NMN well tolerated but reported only non-significant improvement in physical performance overall — with scattered positive signals such as a longer six-minute walk distance and faster gait speed in individual studies, not a consistent benefit.
• Head-to-head trials directly comparing NMN and NR in humans on meaningful outcomes are essentially absent.
• Much of the exciting data — lifespan extension, metabolic rescue — comes from rodents, where translation to humans is uncertain.

The comparison nobody has really run

The striking gap is that almost no rigorous human study has put NMN and NR side by side and measured outcomes that matter. Without that, any claim that one is clearly superior rests on mechanism arguments and animal work, not direct human comparison.

	NR	NMN
Raises blood NAD+ in humans	Yes, dose-dependent (up to ~142%)	Yes, across multiple RCTs
Short-term safety	Good (trials up to ~20 weeks)	Good (10-RCT review, no serious AEs)
Proven healthspan benefit	Not established	Not established (review found non-significant)
Head-to-head vs the other	None	None

The takeaway

Both NMN and NR raise NAD+ in people, and both appear safe at the doses studied. What neither has convincingly demonstrated is a clear human longevity or healthspan benefit, and no solid head-to-head trial exists to crown a winner. If you choose to experiment, do it with modest expectations: you are paying for a biomarker change whose real-world payoff is still an open scientific question.

Sources

• Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial (Conze et al., Scientific Reports, 2019)
• Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials (Cureus, 2024)